On February 3, the United States Court of Appeals for the Federal Circuit (CAFC) affirmed a preliminary injunction granted by the U.S. District Court for the Eastern District of Michigan, holding that the lower court did not abuse its discretion or clearly err in its factual findings. Myco Industries, Inc. started marketing, the AB Max, a device for treating blepharitis in February 2019. The following month, BlephEx, LLC filed a patent application, which issued as U.S. Patent No. 10,449,087 (the ‘087 patent) on October 22, 2019. The ‘087 patent discloses “an instrument for removing debris from an eye during the treatment of an ocular disorder.” The day the ‘087 patent issued, BlephEx sued Myco in the Eastern District of Michigan, alleging that Myco’s AB Max infringed claim 16 of the ‘087 patent. Shortly thereafter, the district court enjoined “Myco and those acting on its behalf from, inter alia, selling, distributing, or offering to sell or distribute the AB Max Product.” Myco appealed.
Recent Posts
- Unveiling The Untapped Potential of Brazil’s Solar Energy Market
- AI Armor: Learn How to Harness AI to Invest in Your Company’s Future
- Other Barks & Bites for Friday, April 19: European Court Rejects Pablo Escobar Trademark; Federal Agencies Launch Anti-Competitive Healthcare Practices Portal; and Reddit Cracks Down on Copyright Infringement
- Thoughts on the USPTO’s NPRM: Not Bad But the Big Challenges Remain
- Patent Filings Roundup: Slow Week in PTAB and District Court, Ideahub Subsidiary Challenges Instituted; Patent Armory Continues the Offensive